Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > EGFRvIII

EGFRvIII

Brief Information

Name:Epidermal growth factor receptor variant III
Target Synonym:
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

EGI-HA2H8-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-EGFRvIII CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human EGFRvIII Protein, His Tag (Cat. No. EGI-HA2H8) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).

EGI-HP2E3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-EGFRvIII CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human EGFRvIII Protein, His Tag (Cat. No. EGI-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

MBS-K020-ELISA
 EGFRvIII ELISA

Immobilized 44 μg EGFRvIII protein/1 mg beads can bind Anti-EGFR Antibody (Cetuximab) with an EC50 of 0.7172 μg/mL (QC tested).

EGI-H5255-MALS-HPLC
Human EGFRvIII, Fc Tag (Cat. No. ) MALS images

The purity of Human EGFRvIII, Fc Tag (Cat. No. EGI-H5255) is more than 90% and the molecular weight of this protein is around 150-184 kDa verified by SEC-MALS.

Bioactivity-ELISA
Human EGFRvIII, Fc TagHuman EGFRvIII, Fc Tag (Cat. No. EGI-H5255) ELISA bioactivity

Immobilized Human EGFRvIII, Fc Tag (Cat. No. EGI-H5255) at 2 μg/mL (100 μL/well) can bind Anti-EGFRvIII Antibody, Human IgG1 with a linear range of 0.1-8 ng/mL (QC tested).

Synonym Name

EGFRvIII

Background

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.The type III EGF deletion-mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors; EGFR gene amplification is correlated with the structural rearrangement of the gene. The EGFRvIII gene has an in-frame deletion of 801 base pairs, corresponding to exons 2–7 in the mRNA, resulting in the deletion of amino acids 30-297 in the extracellular domain and the generation of a glycine at the fusion point

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
EGFRvIII-CAR Phase 1 Clinical Duke University Medical Center Glioblastoma Details
Anti-EGFRvIII-CAR EGFRvIII CAR; Anti-EGFRvIII-CAR Phase 2 Clinical National Cancer Institute, Kite Pharma Glioblastoma Details
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) LXF-821 Phase 1 Clinical University Of Pennsylvania, Novartis Pharma Ag Glioblastoma Details
Etevritamab AMG-596 Amgen Inc Details
hEGFRvIII-CD3 Bi-scFv Duke University Details
EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain) Chembrain Ltd Details
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) CPGJ-602; 602; CPGJ602; CPGJ 602 Phase 2 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Colorectal Neoplasms Details
AMG-595 AMG-595 Amgen Inc Details
GNC-039 GNC-039 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis Details
EGFRvIII-CAR Phase 1 Clinical Duke University Medical Center Glioblastoma Details
Anti-EGFRvIII-CAR EGFRvIII CAR; Anti-EGFRvIII-CAR Phase 2 Clinical National Cancer Institute, Kite Pharma Glioblastoma Details
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) LXF-821 Phase 1 Clinical University Of Pennsylvania, Novartis Pharma Ag Glioblastoma Details
Etevritamab AMG-596 Amgen Inc Details
hEGFRvIII-CD3 Bi-scFv Duke University Details
EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain) Chembrain Ltd Details
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) CPGJ-602; 602; CPGJ602; CPGJ 602 Phase 2 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Colorectal Neoplasms Details
AMG-595 AMG-595 Amgen Inc Details
GNC-039 GNC-039 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message